Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996344 | 0.90 | VDR (1.00) | VDRHDAC6HDAC3 | |
| SCHEMBL19988205 | 0.90 | VDR (1.00) | VDRHDAC6HDAC3 | |
| SCHEMBL14489107 | 0.90 | VDR (1.00) | VDRHDAC6HDAC3 | |
| SCHEMBL12047912 | 0.90 | VDR (1.00) | VDRHDAC6HDAC3 | |
| SCHEMBL3056435 | 0.90 | VDR (1.00) | VDRHDAC6HDAC3 | |
| SCHEMBL12513364 | 0.90 | VDR (0.67) | VDR | |
| SCHEMBL12513363 | 0.90 | VDR (0.67) | VDR | |
| SCHEMBL805084 | 0.88 | VDR (0.73) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL12513106 | 0.88 | VDR (0.65) | VDR | |
| SCHEMBL4156343 | 0.88 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407155-B1 | Formulations of inecalcitol | HYBRIGENICS SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| EP-2407154-B1 | Formulations of 14-epi-analogues of vitamin D | HYBRIGENICS SA (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2360145-B1 | New process for isomerizing fused bicyclic structures and preparation of vitamin D analogs comprising the same | HYBRIGENICS SA (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20120015913-A1 | Formulations of 14-EPI-Analogues of Vitamin D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007512-A1 | NEW FORMULATIONS OF 14 - EPI -ANALOGUES OF VITAMIN D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015915-A1 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20120015914-A1 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007517-A1 | FORMULATIONS OF 14 - EPI -ANALOGUES OF VITAMIN D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007570-A2 | NEW FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D | HYBRIGENICS SA (FR) | 2012-01-19 | — | — | WO | disclosed |
| EP-2407152-A1 | Formulations of 14-epi-analogues of vitamin D | Hybrigenics S.A. (FR) | 2012-01-18 | — | — | EP | disclosed |
| EP-2407155-A1 | Formulations of 14-epi-analogues of vitamin D | Hybrigenics (FR) | 2012-01-18 | — | — | EP | disclosed |
| EP-2360146-A1 | New process for isomerizing fused bicyclic structures and preparation of vitamin D analogs comprising the same | Hybrigenics S.A. (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360145-A1 | New process for isomerizing fused bicyclic structures and preparation of vitamin D analogs comprising the same | Hybrigenics S.A. (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20110184198-A1 | New Process for Isomerizing Fused Bicyclic Structures and Preparation of Vitamin D Analogs Comprising the Same | HYBRIGENICS SA (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2263677-B1 | New therapeutical uses of inecalcitol | HYBRIGENICS SA (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20110015276-A1 | THERAPEUTICAL USES OF INECALCITOL | HYBRIGENICS SA (FR) | 2011-01-20 | — | — | US | disclosed |
| WO-2010145903-A1 | NEW THERAPEUTICAL USES OF INECALCITOL | HYBRIGENICS SA (FR) | 2010-12-23 | — | — | WO | disclosed |
| EP-2263677-A1 | New therapeutical uses of inecalcitol | Hybrigenics (FR) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015913-A1 | Formulations of 14-EPI-Analogues of Vitamin D | CYP24A1, VDR, CYP2R1 | VDR 2/4885HDAC6 2541/4885HDAC3 1341/4885 |
| US-20110184198-A1 | New Process for Isomerizing Fused Bicyclic Structures and Preparation of Vitamin D Analogs Comprising the Same | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC6 4117/4885HDAC3 1257/4885 |
| US-20120015915-A1 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D | CYP24A1, VDR, CYP2R1 | VDR 2/4885HDAC6 2541/4885HDAC3 1341/4885 |
| US-20110015276-A1 | THERAPEUTICAL USES OF INECALCITOL | PTH1R, VDR, CYP24A1 | VDR 2/4885HDAC6 1705/4885HDAC3 566/4885 |
| US-20120015914-A1 | FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D | CYP24A1, VDR, CYP2R1 | VDR 2/4885HDAC6 2541/4885HDAC3 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.